NFL questioned over profits from pink merchandise sold to aid cancer research

Pinterest LinkedIn Tumblr +

Source: The Guardian US Edition – MARTIN PENGELLY

ESPN reports percentage of profits from ‘A Crucial Catch’ campaign kept by league as fundraising month goes on.

Oncology News Austrailai - NFL questioned over missing cash from crucial catch campaignIt has been reported that only a small proportion of funds raised during “A Crucial Catch”, the league’s month-long campaign to support breast cancer research through the sale of pink merchandise and memorabilia, will actually go to help breast cancer research.

The NFL’s campaign, which aims to increase awareness of the need for annual breast cancer screenings “especially for women who are 40 or older”, runs throughout October and sees many players wearing items of pink equipment during games. All such apparel and a number of other items, including pink game balls, will later be auctioned in aid of the American Cancer Society’s Community Health Advocates National Grants for Empowerment (CHANGE) programme. The league also gives fans the chance to donate $10 to the American Cancer Society, by sending a special “NFLPINK” text message.

However, citing data obtained from the NFL, Darren Rovell of ESPN tweeted: “On pink gear, the NFL says it takes a 25% royalty from the wholesale price (1/2 retail), donates 90% of royalty to American Cancer Society.”

At Business Insider, Cork Gaines wrote: “In other words, for every $100 in pink merchandise sold, $12.50 goes to the NFL. Of that, $11.25 goes to the American Cancer Society (ACS) and the NFL keeps the rest.” Gaines added: “The remaining money is then divided up by the company that makes the merchandise (37.5%) and the company that sells the merchandise (50.0%), which is often the NFL and the individual teams.”

Most pink NFL merchandise is sold through the NFL’s online store, making the NFL the company which sells the merchandise and thus receives 50% of the money received…READ MORE

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.